Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia

Ryan K. Shields, M. Hong Nguyen, Liang Chen, Ellen G. Press, Brian A. Potoski, Rachel V. Marini, Yohei Doi, Barry N. Kreiswirth, Cornelius J. Clancy

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant Enterobacteriaceae infections. At our center, ceftazidime-avibactam treatment of carbapenem-resistant Klebsiella pneumoniae bacteremia was associated with higher rates of clinical success (P = 0.006) and survival (P = 0.01) than other regimens. Across treatment groups, there were no differences in underlying diseases, severity of illness, source of bacteremia, or strain characteristics (97% produced K. pneumoniae carbapenemase). Aminoglycoside- and colistin-containing regimens were associated with increased rates of nephrotoxicity (P = 0.002).

Original languageEnglish
Article numbere00883
JournalAntimicrobial agents and chemotherapy
Volume61
Issue number8
DOIs
Publication statusPublished - 01-08-2017

Fingerprint

Carbapenems
Klebsiella pneumoniae
Bacteremia
Enterobacteriaceae Infections
Colistin
Aminoglycosides
Survival
Therapeutics
ceftazidime drug combination avibactam
carbapenemase

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Shields, R. K., Nguyen, M. H., Chen, L., Press, E. G., Potoski, B. A., Marini, R. V., ... Clancy, C. J. (2017). Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrobial agents and chemotherapy, 61(8), [e00883]. https://doi.org/10.1128/AAC.00883-17
Shields, Ryan K. ; Nguyen, M. Hong ; Chen, Liang ; Press, Ellen G. ; Potoski, Brian A. ; Marini, Rachel V. ; Doi, Yohei ; Kreiswirth, Barry N. ; Clancy, Cornelius J. / Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. In: Antimicrobial agents and chemotherapy. 2017 ; Vol. 61, No. 8.
@article{8c1dfcfc11444e4e95cc15caa493adea,
title = "Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia",
abstract = "There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant Enterobacteriaceae infections. At our center, ceftazidime-avibactam treatment of carbapenem-resistant Klebsiella pneumoniae bacteremia was associated with higher rates of clinical success (P = 0.006) and survival (P = 0.01) than other regimens. Across treatment groups, there were no differences in underlying diseases, severity of illness, source of bacteremia, or strain characteristics (97{\%} produced K. pneumoniae carbapenemase). Aminoglycoside- and colistin-containing regimens were associated with increased rates of nephrotoxicity (P = 0.002).",
author = "Shields, {Ryan K.} and Nguyen, {M. Hong} and Liang Chen and Press, {Ellen G.} and Potoski, {Brian A.} and Marini, {Rachel V.} and Yohei Doi and Kreiswirth, {Barry N.} and Clancy, {Cornelius J.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1128/AAC.00883-17",
language = "English",
volume = "61",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. / Shields, Ryan K.; Nguyen, M. Hong; Chen, Liang; Press, Ellen G.; Potoski, Brian A.; Marini, Rachel V.; Doi, Yohei; Kreiswirth, Barry N.; Clancy, Cornelius J.

In: Antimicrobial agents and chemotherapy, Vol. 61, No. 8, e00883, 01.08.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia

AU - Shields, Ryan K.

AU - Nguyen, M. Hong

AU - Chen, Liang

AU - Press, Ellen G.

AU - Potoski, Brian A.

AU - Marini, Rachel V.

AU - Doi, Yohei

AU - Kreiswirth, Barry N.

AU - Clancy, Cornelius J.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant Enterobacteriaceae infections. At our center, ceftazidime-avibactam treatment of carbapenem-resistant Klebsiella pneumoniae bacteremia was associated with higher rates of clinical success (P = 0.006) and survival (P = 0.01) than other regimens. Across treatment groups, there were no differences in underlying diseases, severity of illness, source of bacteremia, or strain characteristics (97% produced K. pneumoniae carbapenemase). Aminoglycoside- and colistin-containing regimens were associated with increased rates of nephrotoxicity (P = 0.002).

AB - There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant Enterobacteriaceae infections. At our center, ceftazidime-avibactam treatment of carbapenem-resistant Klebsiella pneumoniae bacteremia was associated with higher rates of clinical success (P = 0.006) and survival (P = 0.01) than other regimens. Across treatment groups, there were no differences in underlying diseases, severity of illness, source of bacteremia, or strain characteristics (97% produced K. pneumoniae carbapenemase). Aminoglycoside- and colistin-containing regimens were associated with increased rates of nephrotoxicity (P = 0.002).

UR - http://www.scopus.com/inward/record.url?scp=85026380424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026380424&partnerID=8YFLogxK

U2 - 10.1128/AAC.00883-17

DO - 10.1128/AAC.00883-17

M3 - Article

VL - 61

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

M1 - e00883

ER -